Estrogen receptor-alpha positive (ER þ ) breast cancers comprise the majority of human breast cancers, but molecular mechanisms underlying this subtype of breast cancers remain poorly understood. Here, we show that ER þ mammary luminal tumors arising in Tip30 À / À MMTV-Neu mice exhibited increased enrichment of luminal progenitor gene signature. Deletion of the Tip30 gene increased proportion of mammary stem and progenitor cell populations, and raised susceptibility to ER Approximately 75% of human breast cancers are immunostained positive for ERa (ER þ ) at the times of diagnosis, most of which are positive staining for progesterone receptors (PR þ ). In the past decades, substantial progression has been achieved in the diagnosis and treatment of this subtype of breast cancer; however, the cell of origin and underlying mechanisms of ER þ /PR þ breast cancer remains poorly understood.
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Approximately 75% of human breast cancers are immunostained positive for ERa (ER þ ) at the times of diagnosis, most of which are positive staining for progesterone receptors (PR þ ). In the past decades, substantial progression has been achieved in the diagnosis and treatment of this subtype of breast cancer; however, the cell of origin and underlying mechanisms of ER þ /PR þ breast cancer remains poorly understood. 3 Deciphering the regulation of mammary luminal cell differentiation may divulge important clues for identifying the cell of origin for ER þ breast cancers. The mammary epithelium in an adult mammary gland is composed of two lineages of cells: luminal and myoepithelial cells. A small number of mammary cells have been identified as mammary gland stem cells (MaSCs), which can give rise to mature epithelium of either the luminal or myoepithelial lineage through a series of lineage-restricted intermediates. [4] [5] [6] Multilineage progenitors are at an intermediate position in the hierarchy and capable of dividing to luminal-restricted progenitors and myoepithelial-restricted progenitors. The luminal-restricted progenitors are able to differentiate into ER þ and ER À luminal cells, whereas myoepithelial-restricted progenitors are able to produce ER À myoepithelial cells. 5, 7 Most of luminal progenitors in the mammary gland are evidently ER À , but a small population of ER þ luminal progenitors has been identified. [8] [9] [10] Several cellular factors have been demonstrated to regulate various aspects of developmental hierarchy of cell differentiation using genetically-engineered mouse models. For example, MMTV-Wnt1 mice exhibited an expansion of the MaSCs pool and development of both ER þ /PR þ and ER À /PR À types of mammary tumors, whereas MMTV-Neu mice showed no expansion of MaSCs and generated ER À /PR À mammary tumors. 4, 11, 12 Subsequent studies have suggested that MMTV-Neu tumors may arise from lobular alveolar progenitors that are functionally similar to ER À luminal progenitors, 10, 13, 14 whereas MMTV-Wnt1 tumors originate from ductal progenitors, 4, 15, 16 and mammary tumors caused by Brca1 mutations arise from luminal progenitors committed to ER À luminal cell differentiation.
TIP30, also known as HTATIP2 or CC3, 18, 19 is implicated in the pathogenesis of several types of human cancers including breast cancer. [20] [21] [22] There has been a body of evidence showing that it acts as a tumor suppressor involved in the regulation of multiple cellular processes including cell proliferation and apoptosis through influencing ER-mediated transcription, EGFR signaling and nuclear importins in cells. [23] [24] [25] [26] Particularly, loss of Tip30 in mice was found to cause ductal hyperplasia in mammary glands early in life and extensive mammary hyperplasia with age. 27 In addition, deletion of the Tip30 gene in MMTV-Neu mouse was shown to result in increased ER þ luminal cells in the preneoplastic mammary glands and development of ER þ /PR À mammary tumors. 24 Despite these observations, the role of Tip30 in regulation of differentiation of mammary stem cells (MaSCs)/ progenitors remains unknown. Here, we describe that loss of Tip30 not only promoted expansion of mammary stem and luminal progenitor cells in mammary gland, but also influenced luminal progenitor cells fate via upregulation of FoxA1, leading to an increased subpopulation of mature ER þ luminal cells, which may contribute to ER þ mammary tumor development.
Results

Tip30
À / À MMTV-Neu tumors show enrichment of luminal progenitor gene signature and cluster with a subtype of human HER2 þ breast cancer. We previously reported that Tip30 loss promotes development of ER þ luminal carcinomas in MMTV-Neu mouse model. 24 To further explore the role of Tip30 in ER þ luminal carcinomas development, we arrayed mammary tumors arising in MMTV-Neu and Tip30 (Figure 1b) . The gene expression profiles of the tumors were then clustered with human breast cancer profiles that had been annotated using intrinsic clustering. 28 In agreement with previous studies, 29 MMTVNeu tumors do not cluster well with human HER2 þ tumors. We noted that Tip30 À / À MMTV-Neu tumors clustered most closely with human luminal A and B types of breast cancers and secondly with human HER2 þ tumors (Supplementary Figure 1A) , indicating that Tip30 À / À MMTV-Neu tumors are mimicking human luminal types of breast cancers. We also used publicly available gene expression data to analyze for a role of these identified differentially expressing genes in overall patient survival. We observed that low levels of major histocompatibility complex (MHC) in HER þ breast cancer samples were associated with poor survival relative to HER þ breast cancer samples with high levels of MHC (Supplementary Figure 1B) . Intriguingly, when the gene signatures of mouse luminal progenitor, mature luminal and stem/basal cells 30 À / À mice demonstrated that almost all of them were K8-positive, but aSMA-negative, ER-positive and PR-positive (Figures 2c and d) . These results suggest that Tip30 deletion increases susceptibility to the development of ER þ /PR þ luminal subtype of mammary tumors in Balb/c mice.
Tip30 deletion promotes expansion of stem cell and progenitor cell subpopulations. To investigate whether Tip30 loss influences the stem/progenitor cell compartment and epithelial differentiation in the mammary gland, we first used an in vitro system, in which primary MaSCs are propagated on non-adherent substrata to form mammospheres. The number of mammospheres in the mediums reflects the number of stem cells that were plated in the system, whereas the size of mammospheres is a reflection of progenitor cell proliferation. 31 Mammary cells from 5-month-old Tip30 À / À and Tip30 þ / þ mouse mammary glands were isolated and subsequently plated in the mammosphere medium. À / À and Tip30 þ / þ mammary glands were sorted out and subjected to in vitro colony-forming cell assay. 32 suggesting that Tip30 regulates luminal progenitor cell fate. In addition, we previously reported that Tip30 acts in both nucleus and cytosol of breast cells to repress ERa-mediated transcription of c-Myc gene 23 as well as EGFR/PI3K signaling. 24, 25 We also show here that inhibition of PI3K/Akt signaling reduced FoxA1 expression in Tip30 À / À mammary epithelial cells (Supplementary Figure 2) . Hence, it is possible that Tip30 loss enhances EGFR/PI3K signaling, leading to increased FoxA1 expression, which in turn promotes expression of ERa and differentiation of luminal progenitors to ER þ mature luminal cells. Further understanding of this regulatory pathway may contribute to the understanding of molecular mechanisms of normal mammary gland development and ER þ breast carcinogenesis. ER þ /PR þ cells comprise about 7-10% of the luminal epithelial cell population in the normal mature mammary gland, which are rarely proliferative and generally growtharrested by inhibitory factors. 41, 42 Evidently, the majority of human breast cancers at the time of diagnosis were ER þ ductal carcinomas containing proliferative ER þ cancer cells. Moreover, clustered ER þ proliferating cells were frequently detected in ductal hypoplasia and ductal carcinoma in situ, which are significantly associated with human ER þ breast cancer risk. 43 It has been proposed that loss of such inhibitory factors may instigate carcinogenesis of ER þ breast cancers. 44, 45 Given the observations that loss of Tip30 resulted in mammary hyperplasia in female mice of various genetic backgrounds 27 and increased expression of luminal progenitor gene signature in ER þ mammary tumors arising in MMTVNeu mice, we speculate that Tip30 is one of the inhibitory factors in the suppression of differentiation and proliferation of ER þ luminal cells. Loss of Tip30 may result in expansion of ER þ luminal progenitor and mature luminal cells, which provides more cell targets for subsequent oncogenic events.
Nonetheless, the present work has not provided any direct evidence supporting aberrantly increased ER þ progenitors as the cell of origin for ER þ luminal tumors. Thus, further studies will be needed to determine the expanded ER À / À C57BL/6 mice seven generations as described previously. 46 All mice were housed in Animal Facility at Michigan State University. Animal protocols used for this study were approved by Michigan State University IACUC Committee.
Histopathology. Mammary glands and other tissues were removed, fixed in 4% paraformaldehyde solution and then paraffin-embedded. Sections were stained with H&E and examined by two trained investigators and a pathologist who read slides blind to experimental detail. Fresh mammary tissues were frozen with liquid nitrogen after being rinsed with PBS and stored at À 80 1C for western blot assay.
Immunohistochemistry and immunofluorescence. Immunohistochemistry and immunofluorescence for paraffin-embedded tissues were carried out as described previously. 24 Primary antibodies against a-SMA (clone E184, 1 : 50; Millipore, Billerica, MA, USA), CK8 (ks8.7, 1 : 50; Santa Cruz Biotechnology, Dallas, TX, USA), ERa (MC-20, 1 : 50; Santa Cruz Biotechnology) or PR-A (hPRa7, 1 : 50; Labvision, Fremont, CA, USA) were used. Alexa-488-or Alexa-594-conjugated secondary antibody (1 : 200; Molecular Probes, Carlsbad, CA, USA) and 4 0 , 6-diamidino-2-phenylindole for immunofluorescence were used. Immunofluorescence staining of in vitro colonies was as described previously. 24 Briefly, colonies were extracted from matrigel by using PBS-EDTA and then spun to glass slides with a Cytospin4 centrifuge (Thermo Scientific, Kalamazoo, MI, USA). The colonies were fixed with 4% paraformaldehyde, followed by the immunofluorescence staining procedures. Slides were analyzed by confocal laser scanning microscopy (Carl Zeiss, Oberkochen, Germany).
Mammary cell preparation. Mammary glands from 5-month-old virgin female Balb/c mice were chopped and the finely minced tissue was transferred to a digestion mix consisting of serum-free DMEM/F12 (Gibco, Grand Island, NY, USA) containing 0.3 Wünsch units/ml collagenase (Roche, Branford, CT, USA) and 1.5 mg/ml trypsin (Gibco) and then processed to single cells, as previously described. 47 Mammosphere assays. Single-cell suspensions were grown (5000 cells/ well) in 96-well Ultra Low Attachment plates (Corning, NY, USA) with serum-free DMEM/F12 medium (Gibco) containing 20 ng/ml EGF, 20 ng/ml bFGF, 5 mg/ml insulin, 2% B27 and 4 mg/ml heparin (Sigma, St. Louis, MO, USA) for 10 days in 37 1C, 5% CO 2 incubator. Mammospheres were imaged under microscopy and then calculated for the number and diameter from five randomly selected fields per sample at identical magnifications. Only mammospheres exceeding 60 mm in diameter were counted.
Colony-forming assay. 96-well plates were coated with 15 ml growth factor reduced Matrigel (BD Biosciences, San Jose, CA, USA) per well. Two thousand cells were seeded to a well with 1 : 1 DMEM/ F12 medium (Invitrogen) containing Tip30 regulates mammary luminal progenitor fate F Chen et al 10% growth factor reduced Matrigel, 10% FBS (Gibico), 5 mg/ml insulin (Sigma), 10 ng/ml choleratoxin (Sigma) and 10 ng/ml epidermal growth factor (Sigma) and cultured at 37 1C in 5% CO 2 in an incubator for 10 days. Photomicrographs were taken and the colony number and size were calculated as described in Mammosphere assays.
Flow cytometry. CD45
þ /TER119 þ , and CD31 þ cells were removed from dissociated cells using the EasySep biotin selection kit (StemCell Technologies, Vancouver, BC, Canada) according to the manufacturer's instructions. Cells were resuspended in HBSS (Invitrogen) with 2% FBS and incubated with anti-CD24-PE (10 ml/test, Mouse mammary cell enrichment kit, StemCell Technologies), anti-CD49f-FITC (10 ml/test, Mouse mammary cell enrichment kit, StemCell Technologies) or anti-Sca1-APC (0.06 mg/test, eBioscience, San Diego, CA, USA) for 30 min on ice, followed by washing and resuspending in HBSS supplemented with 2% FBS. Analysis and sorting were performed by using a FACSVantage TurboSort SE (BD Biosciences). The data were analyzed using BD FACS Sortware sorter software. À / À virgin mice (n ¼ 6) were collected and allowed to adhere to a collagen coated 96-well plate before fixation and then analyzed by immunocytochemistry with anti-ERa (MC-20, 1 : 50; Santa Cruz Biotechnology) and inverted microscopy (Nikon Eclipse Ti, Melville, NY, USA).
Real-time reverse transcription-PCR. Total RNA was isolated using the RNeasy mini kit (Qiagen, Germantown, MD, USA). Reverse transcription was performed using SuperScript III reverse transcriptase (Invitrogen) and Oligo(dT) primer (Invitrogen). The relative gene expressions were measured by real-time RT-PCR using the gene-specific primers and iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). The RNA polymerase II (RPII) was the endogenous control for each cDNA sample. Primers used were as follows: Notch1, forward: Western blotting. Protein extraction from mouse mammary glands and primary cells, and western blotting were carried out as previously described. 27 Primary antibodies for FoxA1 (H-120, 1 : 500; Santa Cruz Biotechnology), pAkt (193H12, 1 : 1000; Cell Signaling Technology) and Akt (11E7, 1 : 1000; Cell Signaling Technology) were used.
Cell culture and treatment. Primary mammary epithelial cells from Tip30 À / À mammary glands were cultured in mammary epithelial cell growth medium with growth factors, cytokines and supplements (Lonza, Allendale, NJ, USA) at 37 1C in 5% CO 2 in an incubator for 24 h, then treated with NVP-BEZ235 (100 nM) or LY294002 (50 nM) for 48 h.
shRNAs. Short hairpin RNAs (shRNAs) were expressed in primary mammary cells using a lentiviral packaging system as described. 25 Vectors encoding shRNA against mouse FoxA1 or control non-target shRNAs were purchased from Thermo Scientific Dharmacon RNAi Technologies (Pittsburgh, PA, USA). The procedures used to produce retroviruses and to infect target cells were as described previously. 25 Gene expression analysis. Gene expression data was generated using Affymetrix mouse genome 430A 2.0 gene chips and will be available at the GEO at NCBI (USA). Unsupervised hierarchical clustering was conducted using Cluster 3.0 and results were viewed using Java Tree View (Free Software Foundation Inc., Boston, MA, USA software). Ras and EGFR pathway predictions were conducted as previously described 48 Gene set enrichment analysis was conducted as described 49 using a gene set derived from genes that are upregulated in luminal progenitor cells. 30 Statistics. Results were represented as mean ± S.E.M. or ± S.D. as indicated. Statistical significance was assessed with a two-tailed, unpaired t-test. Tumor-free curves were compared using a log-rank (Mantel-Cox) test. Tumor incidences were evaluated with a w 2 -test.
